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Significance of this study
What is already known about this subject?
 ► Health-related quality of life is impaired in type 1 di-
abetes compared with healthy controls.
 ► The Diabetes Health Profile (DHP) has been devel-
oped to assess the psychological and behavioral 
burden of living with diabetes.
What are the new findings?
 ► This is the first psychometrical testing of the DHP-
18 in Norwegian sample of patients with type 1 
diabetes.
 ► Problematic issues were identified regarding factor 
structure, item loadings, internal consistency and 
responsiveness.
How might these results change the focus of 
research or clinical practice?
 ► A revised 14-item DHP version is suggested.
 ► Further clarification on psychometrical properties is 
needed before implementation in clinical practice 
and studies.
AbStrAct
Objective The Diabetes Health Profile-18 (DHP-18) was 
developed to measure disease-specific health-related 
quality of life. It has been translated into Norwegian but 
remains invalidated. The purpose of this paper was to 
examine the psychometric properties of the Norwegian 
DHP-18.
Research design and methods Participants with type 
1 diabetes were recruited from three outpatient clinics 
in Norway. Clinical and sociodemographic data were 
collected, and participants completed the DHP-18 and the 
Short-Form 36 (SF-36). Descriptive analysis, frequencies, 
t-tests and the chi-squared tests were used. Principal axis 
factoring (PAF) and confirmatory factor analysis (CFA) were 
used. Convergent validity was tested using Spearman’s 
correlation between the DHP-18 and SF-36. Reliability was 
tested using Cronbach’s alpha and intraclass correlation 
coefficient.
Results In total, 288 patients were included. No floor 
and ceiling effects were found. A forced PAF analysis 
revealed that three questions had an eigenvalue below 
0.40. In the unforced PAF analysis, one question loaded 
below 0.40, while three questions loaded into a fourth 
factor. The correlation between the DHP-18 and SF-36 
dimensions was low to moderate. Problematic internal 
consistency was observed for the disinhibited eating 
dimension in the forced PAF and in the suggested fourth 
dimension in the unforced PAF. CFA revealed poor fit. The 
test–retest reliability displayed good to excellent values, 
but responsiveness was limited.
Conclusions Problematic issues were identified regarding 
factor structure, item loadings, internal consistency and 
responsiveness. Further evaluation of responsiveness is 
particularly recommended, and using a revised 14-item 
DHP version is suggested.
InTROduCTIOn
Being diagnosed with type 1 diabetes (T1D) 
may affect patients negatively across their 
lifespan, and several studies have shown that 
T1D is associated with impaired health-re-
lated quality of life (HRQoL).1
The term HRQoL was introduced to 
distinguish between quality of life in a more 
general sense and the requirements of clin-
ical medicine and clinical trials.2 However, 
HRQoL continues to have a quite unclear 
definition. In general it is agreed that rele-
vant aspects may vary from study to study, but 
may include aspects such as physical, psycho-
logical, social, and emotional functioning, 
as well as general health, symptoms and 
existential issues.2 Even though some instru-
ments may focus on a single concept, there 
is a consensus that a number of the above 
dimensions should be included in HRQoL 
questionnaires. In general, we distinguish 
between two main types of instruments used 
to measure HRQoL in clinical populations. 
While generic instruments may be used in 
the general population and across disease 
groups, disease-specific instruments have 
been developed to detect more subtle disease 
and treatment-related effects.2 Disease-spe-
cific and generic instruments have a compli-
mentary relationship. For example, generic 
measures can monitor changes in the physical 
functioning of patients over time in relation 
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to population norms, regardless of the cause of change. 
Disease-specific measures can help determine which 
conditions accounted most for a patient’s limitations in 
physical functioning and, therefore, make such measures 
more useful in outcomes research, studies of healthcare 
costs, and clinical practice.3
The Diabetes Health Profile-18 (DHP-18) was devel-
oped with significant patient and clinical input to 
adequately assess the psychological and behavioral 
burden of living with diabetes.4 Because of the difficul-
ties and complexities of defining and measuring the 
patient’s quality of life, the focus of the original DHP 
(DHP-1) was the psychological and behavioral dysfunc-
tioning of the person as a consequence of the impact 
of living daily with diabetes. Therefore, it was consid-
ered important that the measure contained content that 
reflected the outcome from the everyday dynamic inter-
change between the person with diabetes and the envi-
ronment and as a result dysfunctional outcomes could 
be addressed or alleviated through appropriate educa-
tional or therapeutic intervention.5 The ‘Transactional 
Theory of Stress and Coping’ was used as the theoretical 
model underpinning the development of the DHP-1.6 
The rationale for the development of the DHP-18 was 
the same as the DHP-1 with the difference to develop 
an instrument using questions from the DHP-1 question 
set that would be suitable for use across both type 1 and 
type 2. The questionnaire has consequently undergone 
psychometrical testing in both T1D and type 2 diabetes 
(T2D).7
In order to be used in clinical settings and studies, 
psychometrical testing is an essential methodological 
process, that is, testing of reliability, validity and sensi-
tivity to change. While validity concerns whether an 
instrument measures what it is intended to measure, reli-
ability concerns if the instrument at hand yields repro-
ducible results over time under consistent conditions. 
Sensitivity to change is a measure of the ability of an 
instrument to detect clinically relevant differences, for 
example, change in health status.2 Previous research 
has demonstrated that the DHP-18 has displayed high 
levels of validity, reliability and patient acceptability,4 but 
the overall sensitivity to change has been found to be 
limited.8 However, the latter may be related to the way in 
which change was measured, namely by using a generic 
self-reporting question. Thus, potentially limiting the 
ability to detect relevant changes.8 However, even though 
an instrument has displayed acceptable psychometric 
properties in one language, one cannot automatically 
conclude that the same will apply in other languages 
and cultures. Cross-cultural adaptation is consequently 
important.9 No data have been published regarding the 
validity, reliability and sensitivity to change of the Norwe-
gian DHP-18.2 Hence, the aim of this study was to test the 
psychometric properties of the Norwegian version of the 
DHP-18.
ReseaRCH desIgn and meTHOds
Patients
In this cross-sectional, descriptive study, patients diag-
nosed with T1D, 18 years or older, were consecutively 
included during routine follow-up at three diabetes 
outpatient clinics in the southeastern part of Norway 
from May 2015 to November 2016. Sociodemographic, 
clinical and laboratory tests were collected at baseline. 
Sociodemographic data included age, gender, civil status, 
level of education (dichotomized into lower and higher 
levels of education (ie, education beyond the secondary 
level)), work status (either working or not working) and 
smoking status (dichotomized into current and former 
smokers in one group, non-smokers in the other). Clin-
ical data included body mass index, disease duration, 
medication use, comorbidity, diabetes-related complica-
tions and the Wagner classification of foot ulcers. Labo-
ratory data included hemoglobin, C-reactive protein, 
ferritin, vitamin D (25-hydroxy), leukocytes and iron.
To examine the validity, reliability and sensitivity to 
change of the DHP-18, all patients were asked to fill out 
the questionnaires at inclusion (baseline) and after 4–6 
weeks (retest). At retest, patients also completed a ques-
tion concerning their subjective health state; ‘Compared 
to the last time you completed the questionnaire, how do 
you evaluate your condition today? (i) unchanged, (ii) 
improved, or (iii) deteriorated.’ The questionnaires were 
sent by mail, and patients were asked to complete and 
return them in a prestamped envelope. At each center, a 
senior endocrinologist was responsible for study perfor-
mance (ie, served as the local principal investigator).
data collection
Questionnaires
Diabetes Health Profile-18
The DHP-184 consists of 18 questions assessing psycho-
logical and behavioral functioning, divided into three 
dimensions: psychological distress (six questions), 
barriers to activity (seven questions) and disinhibited 
eating (five questions). The scoring method, which is 
applied to the DHP, is based on the widely used Likert 
method of summated scales in which each question is 
scored using a graded scale and summated to provide a 
total score for the specific domain. Each of the 18 ques-
tions is consequently scored on a 0–3 scale, and trans-
formed into a 0–100 scale, where a higher score indicates 
lower levels of HRQoL.8 For the DHP-18, a number of 
different ‘forced choice’ adjective scales are used to 
measure either frequency or intensity which depend 
on the nature of the question asked. The DHP-18 has 
been translated and linguistically validated into Norwe-
gian according to the principles of good practice for the 
translation and cultural adaptation process for patient‐
reported outcome measures (PROM).10
Short-Form 36
The Short-Form 36 (SF-36) is a generic HRQoL ques-
tionnaire designed to assess functional status, well-being, 
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and general perception of health.11 The questionnaire 
consists of 36 questions, which are transformed into eight 
dimensions: physical functioning (10 questions), bodily 
pain (2 questions), vitality or energy level (4 questions), 
social functioning (2 questions), mental health (5 ques-
tions), general health (5 questions), role limitation due 
to physical problems (4 questions), and role limitations 
due to personal or emotional problems (3 questions). An 
additional question reports on health transition over the 
past year. For each question, the raw score was coded and 
transformed into a scale from 0 to 100, with 0 indicating 
the lowest level of function and 100 the highest level of 
function. The questionnaire has been translated into 
Norwegian12 and has been validated among people with 
diabetes.13
Procedure
A standardized inclusion procedure was followed at 
each center. This included baseline collection of socio-
demographic, clinical, laboratory and patient-reported 
outcome data. Moreover, this procedure enabled 
patients to fill out the questionnaires undisturbed at 
the hospital outpatient clinic. While clinical data were 
collected during clinical consultation with an endocri-
nologist, sociodemographic data were self-reported by 
patients. Moreover, laboratory data were based on blood 
samples drawn by a phlebotomist in connection with the 
clinical consultation. All questionnaires were collected 
and checked by a study nurse before the patient left the 
consultation to optimize data completeness and quality. 
Face validity was investigated by distributing the ques-
tionnaire to 10 patients prior to the main study. This 
was done to receive patient input on question content, 
scoring, and structure. Missing values for the DHP-18 
and SF-36 were treated as recommended by Meadows5 
and Ware14: if ≥50% of questions in a dimension had 
been completed, missing values were substituted with the 
mean of the completed questions for that dimension.
statistical analysis
To assess the characteristics of the sample, we used 
descriptive analysis, frequencies, t-tests and the χ2 test. 
Floor and ceiling effects were investigated by calculating 
the percentage of patients scoring either the lowest or 
highest possible dimensional scores. A 15% cut-off value 
for both floor and ceiling effects was used according to 
recommendations in the literature.15 The construct of 
the Norwegian DHP-18 was tested with principal axis 
factoring (PAF) analyses with varimax orthogonal rota-
tion. In accordance with the original validation studies, 
both forced and unforced PAF were used.4 7 In addition, 
a confirmatory factor analysis (CFA) was performed to 
investigate the model fit.
Construct validity was further tested using three 
approaches: (1) convergent validity, (2) discriminant 
validity, and (3) known-group validity.
1. Convergent validity was calculated using binary cor-
relation analysis (Spearman’s r—due to evidence of 
non-normal value distributions) of the DHP-18 and 
SF-36. Before starting the analysis, we set up the fol-
lowing a priori hypothesis:
 – Based on semantic construct, we hypothesized that 
the DHP-18 dimension psychological distress would 
correlate with the SF-36 dimensions mental health, 
vitality, social functioning, general health and role 
emotional.
 – The DHP-18 dimensions barriers to activity and dis-
inhibited eating were hypothesized to display low 
correlations with all SF-36 dimensions.
2. Discriminant validity was calculated by comparing the 
correlation between the three DHP-18 dimensions.
3. Student’s t-test was used to calculate known-group 
validity by comparing DHP-18 scores in patients with 
or without diabetes-related complications and comor-
bidity. DHP-18 scores were also investigated in three 
groups: (A) no complications, (B) one to two compli-
cations, and (C) ≥3 complications. The known-group 
validation was based on the principle that certain spec-
ified groups of patients might be anticipated to score 
differently from others. Thus, the instrument should 
be sensitive to these differences.
Internal consistency reliability was calculated using 
Cronbach’s alpha coefficient, where values above 0.7 are 
regarded as acceptable.2 Test–retest reliability was calcu-
lated using the intraclass correlation coefficient (ICC) in 
patients reporting that their disease state was unchanged 
from baseline to retest (4 weeks’ interval). Values from 
0.70 to 0.90 represent ‘moderate or good reliability’ 
and above 0.90 ‘high or excellent’.2 Responsiveness was 
tested in those patients who reported either deteriora-
tion or improvement in DHP-18 scores from baseline to 
retest, by using paired t-tests. Cohen’s d effect size was 
used to investigate responsiveness and calculated by 
comparing the mean difference between groups, divided 
by the pooled SD. Operational definitions of 0.2, 0.5, 
and 0.8 were categorized as small, medium, and large, 
respectively.16
All tests were two sided, with a 5% significance level. 
Statistical analyses were performed using the Statistical 
Package for the Social Sciences (SPSS V.24, IBM) and 
IBM AMOS V.25.
ResulTs
In total, 332 eligible patients were invited to participate 
in the study. Of these, 288 (87%) patients gave written 
informed consent. Baseline characteristics of the included 
patients are presented in table 1. Except for comor-
bidity (p=0.002), no statistically significant differences 
were observed between genders. A total of 199 patients 
completed the retest, corresponding to 69% of the orig-
inal sample. Two patients did not complete the health 
condition question during the retest and were conse-
quently excluded, leaving 197 patients with complete 
datasets. Compared with responders at the retest, non-re-
sponders were significantly younger (p<0.001), and were 
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Table 1 Sociodemographic and clinical data of included 
patients (n=288)
Age, mean (SD), years 44.8 (13.3)
Age range (min-max) 18–80
Civil status (n=) (missing, n=1)
  Single 38
  Married/cohabitant 231
  Divorced/separated 15
  Widow/widower 3
Educational level (n=)
  Lower education 157
  Higher education 131
Employment (n=) (missing, n=1)
  Working 202
  Not working 85
Smoking (yes) (missing, n=2) 68
Diabetes duration, mean (SD) 23.0 (13.3)
Diabetes duration, range (min-max) 0–63
Insulin pump users (n=) 112
BMI, mean (SD) 26.7 (4.6)
Diabetes complications (n=)
  Neuropathy 38
  Retinopathy 85
  Nephropathy 20
Comorbidity mr_and sr_ yes (n=) 177
Plasma glucose*, mean (SD) (missing, n=2) 9.86 (4.7)
HbA1C, mean (SD) (missing, n=2) 8.16% (1.2)
66 mmol/mol
Figures presented as n= if not otherwise noted, lower 
education, =<university/college; higher education, college or 
university; plasma glucose=not fasting,
BMI, body mass index; mr, medical records; sr, self-reported.
Psychosocial Research
more often male (p<0.001). There were no patients who 
exceeded the limit of 50% missing values in DHP-18, but 
six patients were excluded due to missing data in SF-36. 
No significant floor or ceiling effects were observed.
Validity
Face validity revealed no problematic issues regarding 
either content or scoring. At baseline and retest, 0.3% 
of patients made specific comments on single items in 
the DHP-18 (ie, items 2, 3, 4, 8, 9, 12, 14, 15, 16 and 17). 
Specific comments were related to questions of rele-
vance and meaning. For example, in question 4 several 
commented on the meaning of ‘avoid going out’, which 
in Norwegian can imply anything from going out of 
the house to going to a party. Furthermore, in question 
14 ‘Do you get edgy when out and there is nowhere to 
eat?’, some commented that there is a huge difference 
between getting edgy because you cannot get hold food 
fast enough and getting edgy because you cannot find an 
available table at a restaurant.
Factor loadings of the forced PAF analysis accounted 
for 42% of the variance and are presented in table 2. 
Three questions (4, 13 and 14), all belonging to the 
original barriers to activity dimension, loaded below the 
cut-off of 0.40. The unforced PAF analysis explained 46% 
of the variance and is presented in table 3. One question 
(question 4) loaded below the cut-off of 0.40, while three 
questions from the original barriers to activity dimension 
(11, 13 and 14) loaded into a fourth factor. CFA displayed 
an χ² (132)=329.91, p<0.001, the values of confirmatory 
fit index=0.885 and root mean square error of approxi-
mation=0.071 indicated a poor fit to the data. The items 
did not load strongly on their respective factors and did 
not fit to the standardized λ≥0.60; all items were p<0.001, 
and indicated that the latent variables were not well 
defined by their items. The estimates for psychological 
distress ranged from 0.12 to 40, the estimates for barriers 
to activity ranged from 0.28 to 0.60, and the estimates 
for disinhibited eating ranged from 0.22 to 0.69. Correla-
tions among the three latent variables ranged from (0.02) 
to (0.12).
Convergent validity between the DHP-18 dimensions 
and the SF-36 dimensions revealed, in accordance with 
the a priori hypotheses, an inverse relationship with all 
SF-36 dimensions (table 4). Discriminant validity showed 
an overall low correlation between the DHP-18 dimen-
sions (0.22–0.37). Known-group validation revealed that 
the mean psychological distress was 24.2 vs 21.9 (p=0.02) 
for those with or without complications/comorbidity, 
respectively. No statistically significant differences were 
observed for the barriers to activity and disinhibited 
eating dimensions. When investigating DHP-18 scores 
according to whether patients had no, 1–2 or ≥3 compli-
cations, no significant differences were observed.
Reliability and responsiveness
Internal consistency reliability revealed an overall Cron-
bach’s alpha of 0.79, while dimensional alphas were 0.85 
for psychological distress, 0.70 for barriers to activity, 
and 0.42 for disinhibited eating. When investigating 
item-total statistics, the results indicated that excluding 
question 9 from the disinhibited eating dimension would 
increase the dimensional and overall Cronbach’s alpha 
to 0.78 and 0.83, respectively. When excluding questions 
4, 13 and 14 (all belonging to the barriers to activity 
dimension), which loaded <0.40, the overall alpha for the 
remaining 15 questions was 0.77, and the dimensional 
alpha remained 0.70. When investigating alpha values in 
the fourth factor suggested in the unforced PAF, Cron-
bach’s alpha was 0.52 (questions 11, 13 and 14). The 
overall alpha after excluding questions 4, 9, 13 and 14 in 
the remaining 14 questions was 0.81.
A total of 156/197 (79.2%) reported that their condi-
tion was unchanged from baseline to retest, and ICC 
values were 0.82, 0.76 and 0.74 for psychological distress, 
barriers to activity and disinhibited eating, respectively.
There were a low number of patients reporting either 
improvement (20/197, 10.2%) or deterioration (21/197, 
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Table 2 Forced principal axis factoring (PAF) with varimax orthogonal rotation with Kaiser normalization
Dimensions and questions
Factor Mean 
(SD) Communalities1 2 3
Psychological distress
6. Do you lose your temper if people keep on at you about sugar testing or 
diet?
0.537 0.252 0.005 0.7 (0.8) 0.31
8. Are there more arguments or upsets at home than there would be if you 
did not have diabetes?
0.568 0.000 0.163 0.5 (0.7) 0.37
15. Because of your diabetes, do you get depressed? 0.478 0.308 0.316 0.8 (0.7) 0.43
16. Does your diabetes cause you to lose your temper or shout? 0.835 0.137 0.105 0.8 (0.7) 0.73
17. Do you get touchy or moody about diabetes? 0.812 0.177 0.187 0.8 (0.7) 0.73
18. Do you find yourself losing your temper over small things? 0.720 0.210 0.132 0.6 (0.7) 0.58
Barriers to activity
1. Does food control your life? 0.016 0.159 0.588 1.3 (0.9) 0.40
2. Does having diabetes mean it is difficult staying out late? 0.139 −0.027 0.573 0.4 (0.7) 0.35
3. Does having diabetes mean your days are tied to meal times? −0.007 −0.054 0.756 1.1 (1.0) 0.59
4. Do you avoid going out if your sugar is on the low side? 0.119 −0.058 0.378 0.8 (0.9) 0.17
11. Because of your diabetes, do you worry about getting colds or 
influenza?
0.139 −0.015 0.505 0.4 (0.7) 0.26
13. Do you find it frightening or worrying going into busy or crowded shops? 0.211 0.269 0.219 0.3 (0.6) 0.17
14. Do you get edgy when out and there is nowhere to eat? 0.260 0.179 0.354 0.6 (0.7) 0.24
Disinhibited eating
5. Do you have problems keeping to your diet because you eat to cheer 
yourself up?
0.153 0.752 0.041 0.6 (0.8) 0.61
7. Do you have problems keeping to your diet because you find it hard to 
say no to food you like?
0.114 0.710 −0.018 0.9 (0.8) 0.54
9. When you start eating how easy do you find it to stop? −0.112 −0.608 0.069 2.0 (0.7) 0.40
10. How likely are you to eat something extra when you feel bored or fed 
up?
0.164 0.705 −0.060 1.5 (0.8) 0.53
12. Do you wish there were not so many nice things to eat? 0.112 0.553 0.118 0.9 (1.0) 0.36
Values higher than 0.4 in boldface.
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10.7%). No statistically significant differences were 
observed in any of the dimensional scores between base-
line and retest. In addition, the effect sizes measured with 
Cohen’s d were either undetectable or small. Responsive-
ness is presented in table 5.
dIsCussIOn
In the present study, we investigated the psychometrical 
properties of the Norwegian version of the DHP-18. 
Even though satisfactory psychometric properties were 
observed in a substantial number of aspects, problematic 
issues were identified regarding factor structure, item 
loadings, internal consistency, and sensitivity to change.
Even though we did not observe any problematic issues 
when testing for face validity, several critical comments 
were provided at both baseline and retest. The reason for 
this discrepancy is unclear but may potentially be related 
to the small sample of patients (n=10) participating in 
the face validity test. A plausible explanation for some 
of the critical comments made by patients may be that 
some questions are less relevant almost 20 years after the 
original development of the questionnaire. For instance, 
improved technology such as continuous glucose moni-
toring (CGM) increases hypoglycemic confidence and 
decreases diabetes distress, and CGM contributes to 
significant improvement in diabetes-specific quality of 
life.17 Diabetes distress refers to the worries, concerns, 
and fears that are relatively common among individuals 
who struggle with a progressive and demanding chronic 
disease, and high levels of diabetes distress have been 
linked to problematic diabetes management and poor 
glycemic control.17 18
The forced three-factor PAF analysis revealed that 
the factors consisted of the same single items as in the 
original study, but three questions (4, 13 and 14) loaded 
under the recommended value of 0.40.19 Concerning 
question 4, our results align with the findings of Meadows 
et al.7 Moreover, the fact that more of the questions 
loaded below 0.40 than in previous studies may be related 
to the different patient populations used.7 20 While we 
merely investigated patients with T1D, Meadows et al7 
investigated patients with T2D, and Tan et al20 studied a 
combination of patients with T1D and T2D. To explore 
if another factor structure might be observed in the 
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Table 3 Unforced principal axis factoring (PAF) with varimax orthogonal rotation with Kaiser normalization
Dimensions and items
Factor 
Communalities1 2 3 4
Psychological distress
6. Do you lose your temper if people keep on at you about sugar testing or 
diet?
0.523 0.250 −0.033 0.115 00.31
8. Are there more arguments or upsets at home than there would be if you 
did not have diabetes?
0.617 0.007 0.187 −0.018 0.42
15. Because of your diabetes, do you get depressed? 0.427 0.272 0.171 0.416 0.48
16. Does your diabetes cause you to lose your temper or shout? 0.819 0.133 0.042 0.181 0.73
17. Do you get touchy or moody about diabetes? 0.779 0.160 0.085 0.283 0.72
18. Do you find yourself losing your temper over small things? 0.728 0.212 0.108 0.109 0.60
Barriers to activity
1. Does food control your life? 0.060 0.177 0.699 0.006 0.53
2. Does having diabetes mean it is difficult staying out late? 0.157 −0.043 0.536 0.180 0.34
3. Does having diabetes mean your days are tied to meal times? 0.024 −0.070 0.750 0.172 0.60
4. Do you avoid going out if your sugar is on the low side? 0.089 −0.093 0.269 0.300 0.19
11. Because of your diabetes, do you worry about getting colds 
orinfluenza?
0.088 −0.063 0.365 0.432 0.31
13. Do you find it frightening or worrying going into busy or crowded 
shops?
0.110 0.227 0.015 0.551 0.37
14. Do you get edgy when out and there is nowhere to eat? 0.201 0.139 0.210 0.423 0.28
Disinhibited eating
5. Do you have problems keeping to your diet because you eat to cheer 
yourself up?
0.135 0.741 0.011 0.141 0.61
7. Do you have problems keeping to your diet because you find it hard to 
say no to food you like?
0.116 0.714 −0.002 0.028 0.54
9. When you start eating, how easy do you find it to stop? −0.115 −0.611 0.056 −0.008 0.40
10. How likely are you to eat something extra when you feel bored or fed 
up?
0.156 0.704 −0.059 −0.056 0.53
12. Do you wish there were not so many nice things to eat? 0.108 0.547 0.107 0.099 0.36
Values higher than 0.4 in boldface.
Table 4 Correlation (Spearman’s r) between the Diabetes Health Profile-18 dimensions and the Short Form-36 dimensions
SF-36 dimensions
Diabetes Health Profile-18
Psychological distress Barriers to activity Disinhibited eating
Physical functioning −0.244 −0.280 −0.207
Role physical −0.304 −0.291 −0.174
Bodily pain −0.243 −0.205 −0.167
General health −0.440 −0.265 −0.259
Vitality −0.423 −0.196 −0.333
Social functioning −0.475 −0.297 −0.260
Role emotional −0.422 −0.256 −0.216
Mental health −0.527 −0.307 −0.257
All values are significant with p<0.005. Scores in the range 0.40–0.74 are in boldface.
SF-36, Short-Form 36.
Psychosocial Research
Norwegian validation, we also performed an unforced 
PAF analysis suggesting a four-factor solution. Question 
4, however, remained below the threshold of 0.40. More-
over, results of the CFA indicated a poor fit to the data.
The strongest correlation was, as expected, between the 
psychological distress dimension in the DHP-18 and the 
mental health dimension in the SF-36. Similar findings 
have been reported in other studies.4 7 21 As expected, 
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Table 5 Diabetes Health Profile-18 subdimensions: psychological distress, barriers to activity, disinhibited eating and change 
in health condition from baseline to retest
Condition 
Psychological distress Barriers to activity Disinhibited eating
Baseline Retest
P 
values
Cohen’s 
d Baseline Retest
P 
values
Cohen’s 
d Baseline Retest
P 
values
Cohen’s 
d
Improved, 
mean (SD)
25.6 
(17.0)
27.2 
(18.7)
0.545 −0.1 24.0 
(12.8)
24.7 
(13.8)
0.710 −0.05 38.0 
(13.3)
41.3 
(14.1)
0.205 −0.24
Deteriorated, 
mean (SD)
30.4 
(18.3)
32.2 
(15.0)
0.728 −0.1 26.4 
(17.3)
29.3 
(12.6)
0.433 −0.19 47.0 
(14.6)
44.4 
(14.4)
0.338 0.18
Psychosocial Research
based on few common features, low to moderate correla-
tions were observed between the DHP-18 dimension 
barriers to activity/disinhibited eating and all SF-36 
dimensions. Of course, these findings also support 
discriminant ability and indicate a generally low level 
of overlap between the constructs of the SF-36 and the 
DHP-18. Furthermore, and in accordance with Meadows 
et al,7 estimation of discriminant validity indicated low 
correlation between the DHP-18 dimensions.
Known-group validity was investigated by comparing 
DHP-18 scores in patients with or without comorbidity 
and complications. Even though our findings indicate 
that the DHP-18 can distinguish between these groups, 
we also observed some inconsistencies across the three 
dimensions. Similar findings are reported by Mulhern 
and Meadows.8 A potential explanation may be that 
diabetes-related complications and comorbidity do not 
affect the disinhibited eating dimension to the same 
extent as the other two dimensions do. On the other 
hand, choosing a different parameter to investigate 
discriminant ability could potentially also have yielded a 
different result, for example, comparing newly diagnosed 
patients to those with an established diagnosis. Even 
though previous studies have reported that the DHP-18 
can discriminate between different levels of illness, the 
fact that these results are based on patients with T2D 
limits direct comparison with the current study.7 8 Of 
note, when dividing complications into three groups, no 
significant differences were observed.
Except for the disinhibited eating dimension, good 
internal consistency was found. The low internal consis-
tency of the disinhibited eating dimension is in contrast 
to other studies4 7 20 and may be related to the different 
patient populations investigated.7 20 Based on a more 
detailed analysis of item-total statistics, we observed 
that the removal of question 9 increased the internal 
consistency to an acceptable level.2 In addition, when 
investigating the dimensional alphas in the suggested 
four-factor solution, the internal consistency was low.2
The test–retest reliability showed moderate to excel-
lent values in accordance with recommendations in the 
literature.2 7 The sample size needed for test–retest anal-
ysis has been the subject of some debate.2 22 Some have 
advocated that a sample size of 50 could be sufficient as a 
starting point,23 while others have highlighted the need 
for larger sample sizes and more robust test–retest data.24 
Hence, a strength of our study is the large sample size 
included in the retest analyses.
A central aspect of a PROM is the ability to respond to 
relevant changes in a particular condition, also known as 
sensitivity to change. Optimally, a PROM should be able 
to discriminate between groups of patients who report 
differences in health status. In this study, a marginal 
number reported either improvement or deterioration, 
increasing the risk of a type II statistical error. With this 
limitation in mind, we were not able to observe any statis-
tically significant differences in any of the groups. Other 
studies have also reported low responsiveness.8 25 The 
ability of a disease-specific questionnaire to capture rele-
vant changes in a condition is critical, and future studies 
must, therefore, keep this in mind in order to clarify 
whether the DHP-18 indeed is responsive to change.
In addition to the factors discussed previously, it is of 
course hard to say whether or not different sample char-
acteristics in the current and former studies may explain 
the findings in this study. While patients in the study by 
Meadows et al4 were somewhat younger than our popu-
lation, patients in the study by Mulhern and Meadows8 
were of higher age. However, the latter study investigated 
the validity and reliability of the DHP-18 in a cohort of 
patients with T2D, which consequently might explain 
the large age difference between the studies. Further, 
the level of diabetes-related complications did not differ 
between Mulhern and Meadows8 and our study.
Based on the methodological observations made in 
this study, including that of factor structure, item load-
ings and internal consistency, we argue for excluding 
the following items: item 4 (loading below the recom-
mended limit of 0.40 in both the forced and unforced 
PAF), and items 9, 13 and 14 (either loading under 0.40 
or resulting in weak internal consistency). Therefore, 
using a 14-item version of the Norwegian DHP could be 
suggested (online supplementary appendix 1). However, 
such a choice is not without limitations, particularly since 
it hampers direct comparison to international studies 
that have used the original 18-item version of the DHP.
This study has some limitations in addition to those 
factors previously discussed. The psychometrical testing 
was not performed in T2D, consequently limiting the 
applicability of the results merely to T1D. We evaluated 
change in health status using the patient’s own subjec-
tive experience. Using a more objective marker of disease 
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could have strengthen the analyses. Known-group valida-
tion was investigated by comparing patients with compli-
cations and comorbidities to those without. Of course, 
such a simplistic way of defining known groups may 
be viewed as a limitation. In addition, we do not have 
any information regarding those patients who were 
not included in the study, and even though a consecu-
tive recruitment procedure was undertaken, we cannot 
exclude the risk of a potential recruitment bias. In our 
study, we used SF-36 to investigate criterion validity. 
Based on content in DHP-18 and SF-36 we expected low 
correlations in two of the DHP-18 dimensions compared 
with SF-36. In retrospect, another instrument than the 
SF-36 might have been more proper to measure crite-
rion validation. We are also aware that other question-
naires could be used to measure the aspects that DHP-18 
focuses on. However, the primary rationale for choosing 
the DHP-18 was to investigate the validity, reliability and 
sensitivity of this instrument in a Norwegian population 
of patients with T1D, since this had not been done previ-
ously. Further, if ≥50% of questions in a dimension had 
been completed, missing values were substituted with 
the mean of the completed questions for that dimen-
sion. We realize that use of the ‘half rule’ should be used 
with caution when questions have been ordered hierar-
chically. However, the DHP does not have a hierarchical 
structure to the ordering of its questions and therefore, 
using the ‘half rule’ is the specified method for substi-
tuting missing values for all versions of the DHP.
COnClusIOns
Problematic issues were identified regarding factor struc-
ture, item loadings, internal consistency and respon-
siveness of the Norwegian DHP-18. Further evaluation 
of responsiveness is particularly recommended, and a 
revised 14-question DHP version is suggested.
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